The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and ...

The DCB looks good in select cases, but given its high price tag, exactly when to use it is still up for discussion, say ...

In a wide manufacturing room with white walls and low ceilings, Boston Scientific employees combine components into finished ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted fourth ...

Boston Scientific (NYSE:BSX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a ...

Boston Scientific Corporation develops ... such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters ...

The intracranial stents market is experiencing rapid growth, fueled by the rising incidence of strokes, aneurysms, and ...

Boston Scientific will acquire SoniVie for up to $600 million on 100% basis, adding the TIVUS ultrasound system to its hypertension treatment pipeline. Deal closes in H1 2025.

StockNews.com upgraded shares of Boston Scientific (NYSE:BSX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Friday. A number of other equities analysts ...

The Food and Drug Administration issued a notice on Friday classifying its recall of the Boston Scientific Accolade pacemaker devices as the most serious type of recall. To date, 832 injuries and ...